On November 24, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab ...

In the US, the company had earlier secured market entry dates for its Denosumab biosimilars Bosaya™ (denosumab-kyqq) and ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.

Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & ...

“In a hypothetical health plan covering 1 million lives, adding biosimilar denosumab to a health plan formulary may contribute to significant cost savings; savings can be reinvested to further expand ...

LONDON, Dec. 2, 2025 /CNW/ -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following ...

Biocon Biologics secures market entry date for denosumab biosimilars in Europe and RoW: Our Bureau, Mumbai Tuesday, December 2, 2025, 15:15 Hrs [IST] Biocon Biologics Ltd. (BBL), ...

Biocon Biologics on Tuesday said it has inked a settlement agreement with Amgen Inc., paving the path for the commercialisation of Denosumab biosimilars in Europe and the rest of the world. The ...

On Tuesday, 1586 stocks advanced, 2563 declined and 178 remained unchanged on Bombay Stock Exchange with advance decline ...

Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...

The company informed that this project is one of the six JDAs signed by Raymond, encompassing prime locations of Bandra, ...